Российский кардиологический журнал (Aug 2022)

Thrombosis in unvaccinated and Gam-COVID-Vac-vaccinated patients with COVID-19

  • A. G. Moiseeva,
  • N. Yu. Serova,
  • R. A. Shaikhutdinova,
  • A. S. Zharova,
  • A. V. Korotkikh,
  • R. Yu. Lider,
  • A. N. Kazantsev

DOI
https://doi.org/10.15829/1560-4071-2022-5091
Journal volume & issue
Vol. 27, no. 7

Abstract

Read online

Aim. To analyze the incidence of thrombotic events in unvaccinated and GamCOVID-Vac-vaccinated patients with coronavirus disease 2019 (COVID-19).Material and methods. This prospective study included 316 patients (group 1) vaccinated with two doses of Sputnik V (Gam-COVID-Vac) hospitalized between November 20, 2020 and June 1, 2021 for COVID-19. Group 2 included 754 unvaccinated patients with a positive polymerase chain reaction test for SARSCoV-2.Results. During inhospital period, deaths were recorded only in unvaccinated patients (group 1 — 0%; group 2 — 10,7% (n=87); p<0,0001). Among unvaccinated patients, the following thrombotic events were more common: upper- extremity deep vein thrombosis (group 1 — 0,63% (n=2); group 2 — 5,4% (n=41); p=0,0003), lower-extremity deep vein thrombosis (group 1 — 2,21% (n=7); group 2 — 11,4% (n=86); p<0,0001), pulmonary embolism (PE) (group 1 — 0%; group 2 — 3,4% (n=26); p=0,0008), lower limb arterial thrombosis followed by thrombectomy (group 1 — 0,31% (n=1); group 2 — 12% (n=91); p <0,0001), lower limb arterial retrombosis after retrombectomy (group 1 — 0,31% (n=1); group 2 — 8,7% (n=66); p<0,0001), lower limb amputation (group 1 — 0%; group 2 — 8,7% (n=66); p<0,0001), composite endpoint (group 1 — 3,8% (n=12); group 2 — 55,2% (n=416); p<0,0001). In the long-term follow-up period (125,5±26,5 days), recurrent COVID-19 developed significantly more often in unvaccinated patients (group 1 — 0,63% (n=2); group 2 — 3,6% (n=24); p=0,007). All arterial and venous thromboses, limb amputations were diagnosed only among unvaccinated patients.Conclusion. Vaccination with Sputnik V (Gam-COVID-Vak) prevents the severe COVID-19 with the development of deaths, pulmonary embolism, venous and arterial thrombosis.

Keywords